StreetInsider.com News Articles

Form 8-K Quoin Pharmaceuticals For: Oct 14

Wed, 14 Oct 2026 06:35:00 -0400

si-local-file:///var/storage/secattach/20261014/27183363.html

EMA grants orphan drug status to Quoin's QRX003 for skin disorder

Wed, 14 Oct 2026 06:30:15 -0400

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to its lead product candidate QRX003 for the treatment of Peeling Skin Syndrome.

The designation provides Quoin with incentive benefits including scientific advice on study protocols, fee reductions, and access to EU grants. If the EMA grants marketing authorization, QRX003 would receive 10 years of market exclusivity in Europe for Peeling Skin Syndrome.

According to the company, this marks the eighth regulatory milestone for QRX003 across two indications. The U.S. Food and Drug Administration has previously granted QRX003 Pediatric Rare Disease Designation and Fast Track

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Wed, 14 Oct 2026 06:30:00 -0400

– Company on track to initiate first-ever formal clinical trial in Peeling Skin Syndrome before year end

– Orphan Drug designation milestone provides 10 years of market exclusivity for Peeling Skin Syndrome in Europe after receipt of marketing authorization in the European Union

– Designation Represents Eighth Important Regulatory Milestone for QRX003

– QRX003 has also been granted Pediatric Rare Disease Designation and Fast Track Designation for Peeling Skin Syndrome from US Food and Drug Administration

– In Netherton Syndrome, QRX003 has been granted Orphan Drug Designation in US, Europe

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Wed, 14 Oct 2026 06:30:00 -0400

– Company on track to initiate first-ever formal clinical trial in Peeling Skin Syndrome before year end

– Orphan Drug designation milestone provides 10 years of market exclusivity for Peeling Skin Syndrome in Europe after receipt of marketing authorization in the European Union

– Designation Represents Eighth Important Regulatory Milestone for QRX003

– QRX003 has also been granted Pediatric Rare Disease Designation and Fast Track Designation for Peeling Skin Syndrome from US Food and Drug Administration

– In Netherton Syndrome, QRX003 has been granted Orphan Drug Designation in US, Europe

BTIG Starts Quoin Pharmaceuticals (QNRX) at Buy

Mon, 12 Oct 2026 06:05:48 -0400

BTIG analyst Jeet Mukherjee initiates coverage on Quoin Pharmaceuticals (NASDAQ: QNRX) with a Buy rating and a price target of $14.00.
The analyst comments "Quoin Pharmaceuticals (QNRX) is a clinical-stage biopharmaceutical company developing QRX003, a topical broad-spectrum serine protease inhibitor lotion, for Netherton Syndrome (NS), a rare skin disease with no FDA-approved therapies and an estimated 1,600-3,000 diagnosed pts in the US today. We see QRX003's broad kallikrein inhibition as differentiated and its clinical responses and clean safety profile addressing the large unmet need in NS. Depending on whether a randomized withdrawal study is needed or if the ongoing QRX003-004 study

BTIG Starts Quoin Pharmaceuticals (QNRX) at Buy

Mon, 12 Oct 2026 06:05:48 -0400

BTIG analyst Jeet Mukherjee initiates coverage on Quoin Pharmaceuticals (NASDAQ: QNRX) with a Buy rating and a price target of $14.00.
The analyst comments "Quoin Pharmaceuticals (QNRX) is a clinical-stage biopharmaceutical company developing QRX003, a topical broad-spectrum serine protease inhibitor lotion, for Netherton Syndrome (NS), a rare skin disease with no FDA-approved therapies and an estimated 1,600-3,000 diagnosed pts in the US today. We see QRX003's broad kallikrein inhibition as differentiated and its clinical responses and clean safety profile addressing the large unmet need in NS. Depending on whether a randomized withdrawal study is needed or if the ongoing QRX003-004 study

Form SCHEDULE 13G/A Quoin Pharmaceuticals Filed by: Ikarian Capital, LLC

Wed, 07 Oct 2026 17:14:00 -0400
si-local-file:///var/storage/secattach/20261007/27161977.html

Quoin Pharmaceuticals' QRX003 paper accepted in dermatology journal

Tue, 06 Oct 2026 06:32:45 -0400

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced that a manuscript on its investigational drug QRX003 has been accepted for publication in Dermatology and Therapy, a peer-reviewed journal.
The paper, titled "An Investigational Mechanism-Informed Therapy for Netherton Syndrome: Introduction to QRX003 and a Pediatric Compassionate-Use Case Report," describes QRX003's mechanism of action as a topical serine protease inhibitor lotion for Netherton Syndrome. It includes a case report from Professor Alan Irvine, consultant dermatologist at Children's Health Ireland and professor of dermatology at Trinity College Dublin, documenting his experience treating a pediatric patient under Quoin's Compassionate Use Program.
According to the paper, the treated patient

Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy

Tue, 06 Oct 2026 06:30:00 -0400

Peer-Reviewed Paper Introduces QRX003 and Its Mechanism of Action in Netherton Syndrome
Case Report Details Professor Alan Irvine’s Clinical Experience Treating a Pediatric Patient Under Quoin’s Compassionate Use Program

ASHBURN, Va., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that a manuscript titled “An Investigational Mechanism-Informed Therapy for Netherton Syndrome: Introduction to QRX003 and a Pediatric Compassionate-Use Case Report” has been accepted for publication in a forthcoming issue of

Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy

Tue, 06 Oct 2026 06:30:00 -0400

Peer-Reviewed Paper Introduces QRX003 and Its Mechanism of Action in Netherton Syndrome
Case Report Details Professor Alan Irvine’s Clinical Experience Treating a Pediatric Patient Under Quoin’s Compassionate Use Program

ASHBURN, Va., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that a manuscript titled “An Investigational Mechanism-Informed Therapy for Netherton Syndrome: Introduction to QRX003 and a Pediatric Compassionate-Use Case Report” has been accepted for publication in a forthcoming issue of

Form DEF 14A Quoin Pharmaceuticals For: Nov 12

Fri, 02 Oct 2026 16:42:00 -0400
si-local-file:///var/storage/secattach/20261002/27143060.html

Form EFFECT Quoin Pharmaceuticals

Mon, 28 Sep 2026 06:05:00 -0400
si-local-file:///var/storage/secattach/20260928/27109648.html

Form 424B3 Quoin Pharmaceuticals

Fri, 25 Sep 2026 16:45:00 -0400
si-local-file:///var/storage/secattach/20260925/27107988.html

Lake Street Starts Quoin Pharmaceuticals (QNRX) at Buy

Wed, 23 Sep 2026 08:14:13 -0400

Lake Street analyst Thomas Flaten initiates coverage on Quoin Pharmaceuticals (NASDAQ: QNRX) with a Buy rating and a price target of $20.00.
For an analyst ratings summary and ratings history on Quoin Pharmaceuticals click here. For more ratings news on Quoin Pharmaceuticals click here.
Shares of Quoin Pharmaceuticals closed at $7.01 yesterday.

Form PRE 14A Quoin Pharmaceuticals For: Nov 12

Tue, 22 Sep 2026 16:59:00 -0400
si-local-file:///var/storage/secattach/20260922/27091681.html

Form 8-K Quoin Pharmaceuticals For: Sep 22

Tue, 22 Sep 2026 16:16:00 -0400
si-local-file:///var/storage/secattach/20260922/27091259.html

FDA grants fast track status to Quoin drug for peeling skin syndrome

Tue, 22 Sep 2026 08:30:53 -0400

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced that the U.S. Food and Drug Administration has granted Fast Track Designation to its investigational drug QRX003 for the treatment of Peeling Skin Syndrome, a rare genetic skin disease with no approved treatment.

According to the company, this is the first Fast Track Designation granted for a Peeling Skin Syndrome therapy. It is also the second such designation for QRX003, which previously received Fast Track Designation for Netherton Syndrome in March 2026.

The designation follows the FDA's clearance in July 2026 of Quoin's Investigational New Drug application for QRX003 in Peeling Skin Syndrome, which the company

Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Tue, 22 Sep 2026 08:30:00 -0400

– First-Ever Fast Track Designation Granted for a Peeling Skin Syndrome Therapy

– Second Fast Track Designation Granted to QRX003, in Addition to Netherton Syndrome

– Fast Track Designation Facilitates Development and Expedites Regulatory Review of Therapies Addressing Serious Conditions with Significant Unmet Medical Need

– Follows July 2026 FDA Clearance of the First-Ever IND Submitted for Peeling Skin Syndrome

– Phase 2/3 Study Expected to Initiate in 2H 2026, Enrolling up to 12 Pediatric and Adult Patients in the U.S. and Europe

– Peeling Skin Syndrome Currently Has

Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Tue, 22 Sep 2026 08:30:00 -0400

– First-Ever Fast Track Designation Granted for a Peeling Skin Syndrome Therapy

– Second Fast Track Designation Granted to QRX003, in Addition to Netherton Syndrome

– Fast Track Designation Facilitates Development and Expedites Regulatory Review of Therapies Addressing Serious Conditions with Significant Unmet Medical Need

– Follows July 2026 FDA Clearance of the First-Ever IND Submitted for Peeling Skin Syndrome

– Phase 2/3 Study Expected to Initiate in 2H 2026, Enrolling up to 12 Pediatric and Adult Patients in the U.S. and Europe

– Peeling Skin Syndrome Currently Has

Form S-3 Quoin Pharmaceuticals

Fri, 18 Sep 2026 17:01:00 -0400
si-local-file:///var/storage/secattach/20260918/27081215.html

Form D Quoin Pharmaceuticals

Thu, 10 Sep 2026 17:01:00 -0400
si-local-file:///var/storage/secattach/20260910/27049268.html

Form 8-K Quoin Pharmaceuticals For: Sep 08

Thu, 10 Sep 2026 16:06:00 -0400
si-local-file:///var/storage/secattach/20260910/27048404.html

Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah’s Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU

Thu, 10 Sep 2026 08:30:00 -0400

ASHBURN, Va., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the release of the latest episode in its NETHERTON NOW video series. This episode is about Aminah and is told by her adoptive mother, Laura Wright-Sexton, MD, a board-certified pediatric critical care physician who first met Aminah as a critically ill 10-month-old Netherton Syndrome patient in the pediatric intensive care unit where she practiced. Seven months later, Aminah joined Laura’s family through adoption.

Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah’s Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU

Thu, 10 Sep 2026 08:30:00 -0400

ASHBURN, Va., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the release of the latest episode in its NETHERTON NOW video series. This episode is about Aminah and is told by her adoptive mother, Laura Wright-Sexton, MD, a board-certified pediatric critical care physician who first met Aminah as a critically ill 10-month-old Netherton Syndrome patient in the pediatric intensive care unit where she practiced. Seven months later, Aminah joined Laura’s family through adoption.

Form 4 Quoin Pharmaceuticals, For: Aug 27 Filed by: LANGER DENNIS

Fri, 28 Aug 2026 18:41:00 -0400
si-local-file:///var/storage/secattach/20260828/26999308.html